Navigation Links
UT Arlington undergrad honored for research on antibiotic resistant infection
Date:3/7/2014

,000 deaths in the U.S. each year. Elderly and hospitalized patients are especially susceptible. Last year, the Centers for Disease Control and Prevention named C. difficile one of the three most "urgent drug resistant health threats."

Fordjour saw firsthand the toll that C. difficile could take while volunteering at Baylor Medical Center at Irving. "C. difficile just stood out to me because it's a formidable pathogen. You get sick and you think you're done with it, and it comes back," said Fordjour, who has volunteered 600 hours in the hospital's emergency room.

In a project overseen by Hurdle, Fordjour and Doan tested combinations of current and in development antibiotics against clinically relevant C. difficile strains isolated from patients. He found evidence that combining a currently used antibiotic called rifaximin and an antibiotic called fusidic acid that is still in clinical trials in the U.S. was particularly effective against different strains of C. difficile in lab tests, gaining better results than either drug alone more than half the time.

This combination could also reduce the risk of C. difficile developing resistance to either drug during therapy, he said. The next step will be submitting those results for publication.

"Rifaximin which is used to treat traveler's diarrhea is currently in clinical trials as a treatment for patients who experience multiple episodes of treatment failures for CDI. The problem is that resistance can arise to rifaximin during treatment. We hope the combinations showing improve efficacy over rifaximin alone, could provide a better treatment outcome," Hurdle said.

In addition to Fordjour's work with Hurdle, he is a member of the UT Arlington Honors College and a recipient of the UT System Louis Stokes Alliance for Minority Participation, or LSAMP, grant and a scholar in the Ronald E. McNair Post-baccalaureate Achieveme
'/>"/>

Contact: Traci Peterson
tpeterso@uta.edu
817-521-5494
University of Texas at Arlington
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. UT Arlington study links BPA and breast cancer tumor growth
2. UT Arlington bioengineer to create new nanoparticle system to shore up arterial walls
3. UT Arlington research may unlock enzymes role in disease
4. UT Arlingtons Nguyen named American Heart Association fellow
5. NSF awards to UT Arlington researchers will fuel sustainable solutions
6. 9 UT Arlington educators honored for teaching excellence
7. UT Arlington engineer to design prototype that predicts flash flooding
8. UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline
9. UT Arlington engineer to search for bad algal blooms
10. UT Arlington bioengineer to use hybrid imaging system to see deep tissue
11. UT Arlington engineer wins NSF award to support microfluidic analyses of tissue, cell samples
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT Arlington undergrad honored for research on antibiotic resistant infection
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
... have uncovered a new cellular secret that may explain ... of cancers that makes treatment especially difficult. If the ... -- can be understood well enough to manipulate it, ... with metastatic cancers. , Significance of the Mayo ...
... exposure has already permanently damaged their skin cells, causing ... dark splotches and uneven skin tone over time. But ... known for treating arthritis ?can actually help stop the ... ones. , "These findings on glucosamine may impact the ...
... have taken a potentially powerful new therapy for treating ... the test tube and into animals by demonstrating it ... The research has particularly important implications for the estimated ... both nerves and blood vessels. , The therapy involves ...
Cached Biology News:Mayo Clinic researchers discover cancer cells may move via wave stimulation 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 3Science finds new fix for UV-damaged skin in arthritis treatment 2Science finds new fix for UV-damaged skin in arthritis treatment 3Proteins spur diabetic mice models to grow blood vessels, nerves 2
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... 02, 2015 , ... The TS5-Q is designed for myriad ... to analysis of athletic performance. Producing high-resolution slow-motion video , the TS5-Q ... process with the naked eye. , Slow motion sequences are commonly seen ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... race to make solar cells cheaper and more ... on new designs that exploit nanostructures--materials engineered on ... Using nanotechnology, researchers can experiment with and control ... free electrons--properties that are important for the conversion ...
... 8 RxElite, Inc. (OTC,Bulletin Board: RXEI), a ... products, announced today that as permitted under,the registration ... stockholders to cease using the company,s Registration Statement ... 2008 prospectus until,further advised. This release corrects and ...
... expands SRA footprint in human health services around the ... ... overall,expansion in new markets, SRA International, Inc. (NYSE: SRX ) today,announced the ... President and Chief Financial Officer (CFO) of its new,Global Health Sector (GHS) organization. ...
Cached Biology Technology:New nanostructured thin film shows promise for efficient solar energy conversion 2New nanostructured thin film shows promise for efficient solar energy conversion 3/CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement 2SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 2SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 3
... can be upgraded to the GenePix Autoloader ... analyzes, and saves results for up to ... when the batch is complete. Line-by-line autofocus ... slides. GenePix Pro gives you complete flexibility ...
... a fast, easy to use, reproducible and ... are 15 times faster and 5 times ... 5%). ,The VoluPAC tubes enable the determination ... a cell suspension, resulting in absolute data ...
... your microarray data using Asuragens bioinformatics expertise. ... consultation to extensive data analysis using the ... expertise in combination with the Gene Expression ... experiments., ,Normalization and basic statistical analysis including ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: